

## Scil Proteins Appoints Advisory Board

**Halle, Germany, 11 August, 2010** – Scil Proteins, a private biotech company specialized in the research, development and production of recombinant proteins, today announced that it has completed the formation of its advisory board. The AB is comprised of two scientific experts in the field, Dr. Andreas Menrad and Dr. Jürgen Wahl, as well as the seasoned financial consultant, Rainer Kroell.

Andreas Menrad, PhD, is currently the Vice President of Antibody Therapeutics at Genzyme's European Research site in Cambridge, UK. Prior to this, he was Genzyme's Director of Research and Development. Dr. Menrad has extensive experience in the fields of experimental dermatology, inflammation and oncology as well as antibody engineering, having held positions as Project Team Leader and Director of Antibody Engineering and Anti-Angiogenesis Research at Schering AG. Dr. Menrad graduated from the University of Stuttgart and conducted his PhD at the Max-Planck Institute. In addition, he was a post-doctoral fellow at the Wistar Institute in Philadelphia, Pennsylvania.

Jürgen Wahl, PhD, is the former head of biotech production at Roche in Penzberg, Germany. In his 31 years at Boehringer Mannheim and Roche, Dr. Wahl's activities focused on the fermentation of microorganisms for enzyme production and setting up the mammalian cell culture unit for Epoetin beta, as well as diagnostic and therapeutic antibodies. As Head of Biotech Production, he was also responsible for the development and production of various therapeutic drug substances. Dr. Wahl earned degrees in biochemistry, biology and pharmacy from the University of Tübingen.

Dr. Menrad will be responsible for advising the Pharma business unit of Scil Proteins, focusing on the Affilin<sup>®</sup> technology and Affilin<sup>®</sup> product development, while Dr. Wahl will advise the recombinant protein production business unit, focusing on process development and GMP manufacturing.

Rainer Kroell holds a diploma in business studies from the University of Passau and gained his specific qualification as tax advisor in 1997 and his certification as an auditor in 2000. In 1999, he co-founded GKK Partners and is now Senior Partner of this recognized and well-known company for tax consultation and auditing in Munich, Germany. Mr. Kroell has also a focus on biotechnology and he supports Scil Proteins in various financial and taxation issues.

"We are delighted to have won these experts from the biopharmaceutical and financial industry for our advisory board. They will support and reinforce the development of the Affilin<sup>®</sup> technology, our protein based therapeutic drug pipeline candidates and our microbial focussed GMP Business. The board will also assist our Company to further run its integrated business model in drug discovery and protein manufacturing," said Dr. Ulrike Fiedler, CEO of Scil Proteins.

## About Scil Proteins

Scil Proteins specializes in research, development and production of recombinant proteins. Scil Proteins is actively involved in two business areas: (1) Scil Proteins Pharma discovers and develops innovative bio-pharmaceutical products on the basis of the Affilin<sup>®</sup> technology, and (2) Scil Proteins Production produces recombinant proteins as a contract manufacturing organization for research, clinical studies and market. To learn more about Scil Proteins please visit [www.scilproteins.com](http://www.scilproteins.com)

Contact	
Dr. Henning Afflerbach CBO Scil Proteins GmbH t: +49 (0) 3 45 2799 63 65 e: <a href="mailto:henning.afflerbach@scilproteins.com">henning.afflerbach@scilproteins.com</a>	Dr. Douglas Pretsell Senior Account Director College Hill t: +49 (0) 89 5700 1806 e: <a href="mailto:douglas.pretsell@collegehill.com">douglas.pretsell@collegehill.com</a>

## Notes for editors:

### About Affilin<sup>®</sup> Therapeutics

Scil Proteins Affilin<sup>®</sup> therapeutics platform has been designed for the rapid selection of novel pharmaceutical proteins with high specificity for disease relevant targets. Affilin<sup>®</sup> therapeutics are small, very stable and perfectly suited for penetration of diseased tissue and application in destabilizing milieu conditions. As such, Affilin<sup>®</sup> therapeutics enter indication areas where other more complex and less stable molecules remain ineffective.

Affilin<sup>®</sup> therapeutics are so called scaffold proteins derived from variations of the natural protein Ubiquitin, a protein with ubiquitous distribution pattern in the human body. Due to the high degree of sequence conservation of their scaffold Ubiquitin Affilin<sup>®</sup> therapeutics bear very low immunogenic potential and offer predictive immunogenicity screening in relevant animal models. Scil Proteins proprietary Multi-Affilin<sup>®</sup> platform allows the precise modulation of pharmacokinetic parameters of Affilin<sup>®</sup> therapeutics resulting in serum half lives applicable for acute and chronic treatment settings. Scil Proteins Affilin<sup>®</sup> and Multi-Affilin<sup>®</sup> platforms are broadly patent protected for a comprehensive freedom to operate on multiple disease targets of choice.